Hugo dataset:

data:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=gse78220


paper:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808437/


We analyzed the whole exome sequences (WES) of 38 pretreatment (pembrolizumab, nivolumab) melanoma tumors (responding, n=21; non-responding, n=17; total 34 of 38 pretreatment; 4 of 38 early on-treatment; 14 of 38 patients with prior MAPKi treatment; Table S1A)

response:These response patterns were based on irRECIST